Reproduction permitted for personal use only. For reprints and reprint permission, contact reprints@wistechnology.com.
Madison, Wis. - The blood-brain barrier is a big problem when it comes to getting drugs into the brain, and researchers at the
University of Wisconsin-Madison believe they have found a way to address the problem by using stem cells.
The findings are the result of a collaborative study funded with a grant from the
National Institutes of Health and
led by UW-Madison professor of chemical and biological engineering
Eric V. Shusta, who described the experiment in a recent online edition of the
Journal of Neurochemistry.
For this study, researchers used neural stem cells derived from the fetal brains of rats, and co-cultured them along with blood-brain barrier cells - endothelial cells that make up the blood-brain barrier. They found that the stem cells could have a profound effect on sealing the blood-brain barrier, which happens very early in development.
Although the
blood-brain barrier protects the brain from chemicals and other harmful agents, it also has frustrated neuroscientists and drug companies because it restricts the administration of drugs.
As Shusta explained, the blood-brain barrier "dictates traffic in and out of the brain."
Teaming upShusta's research team also includes
UW-Madison School of Medicine and Public Health professor and stem cell authority
Clive Svendsen, and UW-Madison doctoral fellow
Christian Weidenfeller.
In essense, they have demonstrated that developing brain cells can release factors that might coax small blood vessels to exhibit the properties of the blood-brain barrier. Svendsen believes the finding could produce insights into how drugs could overcome the barrier and treat disease.
"The idea is that we can use this process to mimic what happens in normal development so that we can make a better model of the blood-brain barrier, and that's important for testing drugs," he said.
Their next move will be to reproduce the findings using human endothelial cells and neural stem cells, which would represent a breakthrough because there is no reliable model for the human blood-brain barrier and because many promising drugs are made up of molecules too big to pass through the human barrier.
Handy stem cellsAccording to Svendsen, studying the human cells could produce results after a year or more of work, and he noted that researchers at UW-Madison have access to a lot of different types of human stem cells.
"The interactions between the stem cells and endothelial cells hasn't really been explored before," he noted. "It's another area I think where stem cells will come in handy, and having an in vivo model that is really sealed gives you a chance to test whether drugs will get through the blood-brain barrier before giving them to animals or people."
Related stories
New stem cell company an early mover
Researcher wants to commercialize adult stem cell discovery
Wisconsin researchers defend stem cell company
State puts up $1 million for James Thomson's new stem cell startup
Thomson lends perspective to stem cell expectations